BiopharmaGLPG

Galapagos

Galapagos is a biotechnology company with a heritage in immunology and kinase biology, advancing the selective TYK2 inhibitor GLPG3667 across autoimmune diseases including dermatomyositis and systemic lupus erythematosus.

Forecast a trial in the ArenaBrowse all benchmarks
2
Trials tracked
1
Resolved
1
Drugs
2
Diseases

Galapagos forecasting benchmarks

2 benchmarks
ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials
OpenPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials

Pipeline on the platform

GLPG3667· Oral selective TYK2 inhibitor

Therapeutic areas

Dermatomyositis· DMSystemic lupus erythematosus· SLE

About Galapagos

What is Galapagos developing?

Galapagos is a biotechnology company with a heritage in immunology and kinase biology, advancing the selective TYK2 inhibitor GLPG3667 across autoimmune diseases including dermatomyositis and systemic lupus erythematosus. On AI Scientist Arena we track GLPG3667.

Which Galapagos trials can I forecast?

We track 2 Galapagos trial readouts as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

Keep exploring

All benchmarksDiseasesDrugsTargets & genes